New article to read! Potassium binders and continuation of renin–angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure.

🔗 doi.org/10.1111/joim.70087

#CKD #Hyperkalaemia #heartfailure #RAASi

Four graphs compare cumulative incidence over time (0-2 years) for CCB and RAASi treatments. Graphs A and B show primary income, unadjusted and adjusted respectively, while C and D show secondary income, also unadjusted and adjusted. Number at risk included.

Among children with chronic kidney disease, first-line #RAASi were associated with lower risk of CKD progression and improved blood pressure control compared to #CCB.

ja.ma/4dslbaj

Hyperkalemia and Suboptimal RAASi Dosing Associated With Negative Outcomes | Docwire News A literature review shed light on hyperkalemia, including a significant increase among patients with chronic kidney disease (CKD) despite treatment with RAASi.

A literature review showed a significant increase in #hyperkalemia among patients with #CKD despite treatment with #RAASi. #nephsky #nephrology #kidneydisease www.docwirenews.com/post/hyperka...

Study Demonstrates Benefits of SGLT2i for Hyperkalemia Risk in Clinical Setting | Docwire News Use of SGLT2i with RAASi in those with diabetes, heart failure, or chronic kidney disease is associated with reduced risk for hyperkalemia in the clinical setting, a study found.

Use of #SGLT2i with #RAASi is associated with reduced risk for #hyperkalemia in the clinical setting, a study found. #nephsky #nephrology #kidneydisease www.docwirenews.com/post/study-d...

Efficacy of SZC for Optimizing RAASi Treatment in DKD | Docwire News A study examined the efficacy of adding sodium zirconium cyclosilicate (SZC) to allow patients with stage 3-4 diabetic kidney disease to maintain treatment with RAASi.

A study assessed the efficacy of adding sodium zirconium cyclosilicate to allow patients with stage 3-4 DKD to maintain RAASi use. #kidneywk #nephrology #nephsky #raasi #diabetickidneydisease

Agreed. Been there with #RAASi, #SGLT2i, etc.

Physiologic rise in Cr/decline in eGFR is not pathologic

Carry on

Hyperkalemia management: a multidisciplinary expert panel’s perspective on the role of new potassium binders - Heart Failure Reviews Hyperkalemia is a potentially life-threatening condition frequently encountered in clinical practice, particularly among patients with chronic kidney disease, heart failure, diabetes, and hypertension...

repost: your #chf patient is on #GDMT and develops hyperkalemia. these 2 meds can help.

#arbs #arni #MRAs Lokelma #SZC #RAASi #cardiosky #cvprev

link.springer.com/article/10.1...

Extended real-world treatment with the K+ binder #SZC was effective at main- taining normokalemia, and was associated with a greater uptake of #RAASi, a reduced rate of #HHF, and improvements in cardiac biomarkers in patients with #HFrEF.

link.springer.com/content/pdf/...

🖇️Let's join in to strengthen our beliefs & clarify our notions about Optimal #RAASi use.

x.com/ISNkidneycare/… x.com/ISNkidneycare/…

🖇️Let's join in to strengthen our beliefs & clarify our notions about Optimal #RAASi use.

x.com/ISNkidneycare/… x.com/ISNkidneycare/…